Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2880458rdf:typepubmed:Citationlld:pubmed
pubmed-article:2880458lifeskim:mentionsumls-concept:C0681867lld:lifeskim
pubmed-article:2880458lifeskim:mentionsumls-concept:C0686347lld:lifeskim
pubmed-article:2880458lifeskim:mentionsumls-concept:C0030077lld:lifeskim
pubmed-article:2880458lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:2880458pubmed:issue5lld:pubmed
pubmed-article:2880458pubmed:dateCreated1987-3-6lld:pubmed
pubmed-article:2880458pubmed:abstractTextA 6-month, double-blind, placebo-controlled study of oxypertine in tardive dyskinesia is described. Results suggest that any beneficial effect noticed initially is not sustained. When this effect is compared with the time course of development of supersensitivity after neuroleptics as reported in the literature, it becomes apparent that the drug, despite its different mechanism of action, behaves like any other conventional neuroleptic. On the basis of the findings, the authors feel that all proposed anti-dyskinetic drugs should be subjected to longer, controlled trials to prove their clinical efficacy.lld:pubmed
pubmed-article:2880458pubmed:languageenglld:pubmed
pubmed-article:2880458pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2880458pubmed:citationSubsetIMlld:pubmed
pubmed-article:2880458pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2880458pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2880458pubmed:statusMEDLINElld:pubmed
pubmed-article:2880458pubmed:monthNovlld:pubmed
pubmed-article:2880458pubmed:issn0001-690Xlld:pubmed
pubmed-article:2880458pubmed:authorpubmed-author:FreemanH LHLlld:pubmed
pubmed-article:2880458pubmed:authorpubmed-author:SoniS DSDlld:pubmed
pubmed-article:2880458pubmed:authorpubmed-author:SampathGGlld:pubmed
pubmed-article:2880458pubmed:authorpubmed-author:BamrahJ SJSlld:pubmed
pubmed-article:2880458pubmed:issnTypePrintlld:pubmed
pubmed-article:2880458pubmed:volume74lld:pubmed
pubmed-article:2880458pubmed:ownerNLMlld:pubmed
pubmed-article:2880458pubmed:authorsCompleteYlld:pubmed
pubmed-article:2880458pubmed:pagination446-50lld:pubmed
pubmed-article:2880458pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2880458pubmed:meshHeadingpubmed-meshheading:2880458-...lld:pubmed
pubmed-article:2880458pubmed:meshHeadingpubmed-meshheading:2880458-...lld:pubmed
pubmed-article:2880458pubmed:meshHeadingpubmed-meshheading:2880458-...lld:pubmed
pubmed-article:2880458pubmed:meshHeadingpubmed-meshheading:2880458-...lld:pubmed
pubmed-article:2880458pubmed:meshHeadingpubmed-meshheading:2880458-...lld:pubmed
pubmed-article:2880458pubmed:meshHeadingpubmed-meshheading:2880458-...lld:pubmed
pubmed-article:2880458pubmed:meshHeadingpubmed-meshheading:2880458-...lld:pubmed
pubmed-article:2880458pubmed:meshHeadingpubmed-meshheading:2880458-...lld:pubmed
pubmed-article:2880458pubmed:meshHeadingpubmed-meshheading:2880458-...lld:pubmed
pubmed-article:2880458pubmed:meshHeadingpubmed-meshheading:2880458-...lld:pubmed
pubmed-article:2880458pubmed:meshHeadingpubmed-meshheading:2880458-...lld:pubmed
pubmed-article:2880458pubmed:meshHeadingpubmed-meshheading:2880458-...lld:pubmed
pubmed-article:2880458pubmed:year1986lld:pubmed
pubmed-article:2880458pubmed:articleTitleOxypertine in tardive dyskinesia: a long-term controlled study.lld:pubmed
pubmed-article:2880458pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2880458pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2880458pubmed:publicationTypeControlled Clinical Triallld:pubmed